ADCTClinical•prnewswire•
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Sentiment:Positive (85)
Summary
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by prnewswire